Amy Kunchok, MBBS, MMed; Allen J. Aksamit Jr, MD; John M. Davis III, MD, MS; et al.
open access
JAMA Neurol. 2020;77(8):937-946. doi:10.1001/jamaneurol.2020.1162
This case-control study examines the inflammatory CNS event outcome among patients with an autoimmune disease who were treated with tumor necrosis factor inhibitors.
Robert Hurford, MRCP; Frank J. Wolters, PhD; Linxin Li, DPhil; et al.
open access
JAMA Neurol. 2020;77(8):947-954. doi:10.1001/jamaneurol.2020.1326
This cohort study examines the age-specific prevalence and prognosis of asymptomatic intracranial stenosis in British patients with transient ischemic attack and minor stroke.
Antoine Leuzy, PhD; Ruben Smith, MD, PhD; Rik Ossenkoppele, PhD; et al.
open access
JAMA Neurol. 2020;77(8):955-965. doi:10.1001/jamaneurol.2020.0989
This diagnostic study examines the use of RO948 F 18 in tau positron emission tomographic imaging as a diagnostic marker for identification of Alzheimer disease compared with magnetic resonance imaging and cerebrospinal fluid measures.
Jonathan M. Coutinho, MD, PhD; Susanna M. Zuurbier, MD, PhD; Marie-Germaine Bousser, MD, PhD; et al.
free access
JAMA Neurol. 2020;77(8):966-973. doi:10.1001/jamaneurol.2020.1022
This randomized clinical trial examines the differences in recovery, mortality, and other clinical results of endovascular treatment with guideline-based standard medical care vs standard medical care alone provided to patients with cerebral venous thrombosis.
Susanna Brauner, MD, PhD; Ann Eriksson-Dufva, MD; Max Albert Hietala, MD, PhD; et al.
free access
JAMA Neurol. 2020;77(8):974-981. doi:10.1001/jamaneurol.2020.0851
This cohort study compares the use of rituximab in patients with refractory and new-onset generalized myasthenia gravis as well as in patients receiving conventional immunotherapy.
Paula R. Clemens, MD; Vamshi K. Rao, MD; Anne M. Connolly, MD; et al.
open access
has audio
JAMA Neurol. 2020;77(8):982-991. doi:10.1001/jamaneurol.2020.1264
This phase 2 randomized clinical trial evaluates the safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping
-
Podcast:
Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Kartik Bhatia, MBBS, MS, PhD; Vitor Mendes Pereira, MD; Timo Krings, MD; et al.
free access
JAMA Neurol. 2020;77(8):992-999. doi:10.1001/jamaneurol.2020.0825
This cohort study assesses the rate of major periprocedural neurological complications in Canadian children following vein of Galen malformation embolization with major procedural and strategic contributors.
Michelle R. Caunca, PhD; Michelle C. Odden, PhD; M. Maria Glymour, ScD; et al.
free access
JAMA Neurol. 2020;77(8):1000-1007. doi:10.1001/jamaneurol.2020.0860
This cohort study examines the association between cumulative exposure to residential segregation during 25 years of young adulthood and cognitive performance in midlife among black individuals in the United States.
Joke De Vocht, MSc; Jeroen Blommaert, MSc; Martijn Devrome, MSc; et al.
open access
has multimedia
JAMA Neurol. 2020;77(8):1008-1017. doi:10.1001/jamaneurol.2020.1087
This case-control study examines the use of fluorine 18–labeled fluorodeoxyglucose positron emission tomographic imaging to detect glucose metabolic changes in individuals who are presymptomatic carriers of a mutation in the C9orf72 gene that leads to amyotrophic lateral sclerosis and frontotemporal dementia.
-
Video:
Relative Glucose Metabolism on Fluorine 18–Labeled Fluorodeoxyglucose Positron Emission Tomographic (PET) Imaging in PreSxC9 Participants vs Controls